Treatment of Refractory Chronic Pruritus of Unknown Origin With Tofacitinib in Patients With Rheumatoid Arthritis

JAMA Dermatol. 2019 Dec 1;155(12):1426-1428. doi: 10.1001/jamadermatol.2019.2804.

Authors

Fang Wang^{1

2}, Caroline Morris¹, Nancy D Bodet^{1

2}, Brian S Kim^{1

2

3

4}

Affiliations

¹ Division of Dermatology, Department of Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri.
² Center for the Study of Itch, Washington University School of Medicine in St Louis, St Louis, Missouri.
³ Department of Anesthesiology, Washington University School of Medicine in St Louis, St Louis, Missouri.
⁴ Department of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, Missouri.

PMID: 31532472
DOI: 10.1001/jamadermatol.2019.2804

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Arthritis, Rheumatoid / complications
Arthritis, Rheumatoid / drug therapy*
Chronic Disease / drug therapy
Female
Follow-Up Studies
Humans
Male
Middle Aged
Piperidines / therapeutic use*
Protein Kinase Inhibitors / therapeutic use*
Pruritus / complications
Pruritus / diagnosis
Pruritus / drug therapy*
Pyrimidines / therapeutic use*
Severity of Illness Index
Treatment Outcome

Substances

Piperidines
Protein Kinase Inhibitors
Pyrimidines
tofacitinib

Grants and funding